Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerClinical and pathological implications of miRNA in bladder cancerNeoplasia: the second decade.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.Systemic therapy in bladder cancerExpression of FGFR3 Protein and Gene Amplification in Urinary Bladder Lesions in Relation to Schistosomiasis.Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer.Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder.Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNAA positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.The War on Cancer rages on.Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids.Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.Improving Systemic Chemotherapy for Bladder Cancer.Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patientsDetection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing.Role of Non-Coding RNAs in the Etiology of Bladder Cancer.Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.Diagnostic and Prognostic Implications of FGFR3/Ki67 Papillary Bladder Cancers
P2860
Q24628746-C470EA94-B6A5-4C9B-90C5-4DE73C24B4B8Q27004262-808059AB-B6C3-4008-A995-5FE337FCD9DFQ30484000-BEF00067-B4A0-480F-8617-0E249BD80B22Q33526301-B77CA764-C256-49EC-8218-B32506B2E626Q33578564-C9264F20-A783-4A0E-BA1B-955F39A1E751Q33646072-B0D1E190-EE47-4816-A5CF-6954B211EAC4Q33778439-BE9D3147-360D-4919-8266-B48C98F72875Q36014309-8A377A29-6773-4B91-8D5E-DDBB1DAFE59AQ36144821-27A1272A-6517-405C-9199-7A4EC56D6460Q37113604-EE8641F1-6486-4576-A5BD-846885225860Q37363038-A9DE62FD-3F50-4EB5-8A8B-222B4F0995A4Q37478602-6B6B2A40-A02D-42A4-896A-546A214182AAQ37810251-EE15E74E-CF0A-4D8A-A837-AAF7013F5001Q38216129-6A1F6D67-4A7D-4DBA-8079-6E0D9BE4E288Q38272240-3049DAC4-97EA-417C-824D-0110E6B679A8Q38618562-953E42B0-07AE-4AE1-9196-20A2BA5F15F1Q38777610-B7DDDB82-8763-4953-B8A8-FF700B4E62D5Q41584915-7B4E1754-A41E-46AF-AF9B-C521BEA36E30Q41833981-1B59C4CE-3BBF-47C0-BBC7-8FFA4C0C202BQ42936880-6E83000D-46E3-42CE-9EEA-1562DA1BD7ABQ46236214-E655B9AE-AB61-4EDF-8478-BDE12491EFE7Q51018774-D3276702-A710-4782-9D2F-C45D9A508A6CQ53239118-C7A596A7-97BC-449A-8D2C-C944200515FFQ58697359-24443993-5320-493B-B87D-C59D88BB65A4
P2860
Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@ast
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@en
type
label
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@ast
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@en
prefLabel
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@ast
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@en
P2093
P2860
P356
P1433
P1476
Fibroblast growth factor recep ...... ncy of chromosome alterations.
@en
P2093
Arndt Hartmann
Ellen C Zwarthoff
Ines Kania
Joerg Schubert
Johanna M M van Oers
Kerstin Junker
P2860
P356
10.1593/NEO.07178
P577
2008-01-01T00:00:00Z